Clinical Trials
171 trialspreEMBER
Eli Lilly and Company
Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients
Ohio State University Comprehensive Cancer Center
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
GATHER
Centre Henri Becquerel
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Akeso
DETOXp
Montefiore Medical Center
SPECTACLE
Fudan University
Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer
Cedars-Sinai Medical Center
UC HER
National Taiwan University Hospital
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
University of California, San Francisco
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
Tianjin Medical University Cancer Institute and Hospital
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
Nanfang Hospital, Southern Medical University
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer
AntiCancer Research Jamaica
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
FAP PET/CT for Staging Patients With Breast Cancer
Odense University Hospital
QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.
Fudan University
BabyTEARS
Dana-Farber Cancer Institute
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Shanghai Henlius Biotech
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Xijing Hospital
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Fudan University
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Shanghai Henlius Biotech
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Mayo Clinic
BERLIN
Yale University
EPPIL
Institut Jean-Godinot
VIOLET
Mario Negri Institute for Pharmacological Research
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
SERENA-1b
AstraZeneca
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
George Washington University
NELOPHER
Cancer Care Hospital & Research Centre Foundation, Lahore
RACE
Fudan University
A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
Fudan University
RECLAIM
Fudan University
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
Henan Cancer Hospital
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
Peking University Cancer Hospital & Institute
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Emory University
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
LUMInova
TNC Nutrición Terapéutica S.L.
SATROPIN
MedSIR
STORM
Fudan University
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
DNACDKHR
Peking University People's Hospital